Janux Therapeutics (JANX) Non-Current Assets (2020 - 2026)

Janux Therapeutics (JANX) has reported Non-Current Assets for 7 consecutive years, with $26.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets fell 4.58% year-over-year to $26.2 million; the TTM figure through Mar 2026 stood at $105.2 million (down 7.28% YoY), while the FY2025 annual figure was $25.7 million, down 7.8% from the prior year.
• Non-Current Assets improved to $26.2 million in Q1 2026 per JANX's latest filing, from $25.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $32.2 million in Q2 2023 and bottomed at $3.9 million in Q1 2022.
• Historically, Non-Current Assets has averaged $27.6 million across 5 years, with a median of $28.7 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 12597.67% — and 2024, when it slipped 10.64%.
• Janux Therapeutics' Non-Current Assets stood at $31.6 million in 2022, then dropped by 1.28% to $31.2 million in 2023, then fell by 10.64% to $27.8 million in 2024, then dropped by 7.8% to $25.7 million in 2025, then rose by 1.94% to $26.2 million in 2026.
• Business Quant data shows JANX's Non-Current Assets at $26.2 million in Q1 2026, $25.7 million in Q4 2025, and $26.7 million in Q3 2025.